Improving Sperm Oxidative Stress and Embryo Quality in Advanced Paternal Age Using Idebenone In Vitro-A Proof-of-Concept Study

被引:21
|
作者
Nikitaras, Victoria [1 ,2 ]
Zander-Fox, Deirdre [2 ,3 ,4 ,5 ,6 ]
McPherson, Nicole O. [1 ,2 ,7 ]
机构
[1] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5005, Australia
[2] Univ Adelaide, Adelaide Hlth & Med Sch, Adelaide, SA 5005, Australia
[3] Repromed, Dulwich, SA 5065, Australia
[4] Univ South Australia, Dept Bioengn, Adelaide, SA 5072, Australia
[5] Monash Univ, Clayton, Vic 3800, Australia
[6] Monash IVF Grp, Richmond, Vic 3168, Australia
[7] Univ Adelaide, Freemasons Ctr Male Hlth & Wellbeing, Adelaide, SA 5005, Australia
关键词
reactive oxygen species; male infertility; in vitro fertilization; assisted reproductive technology; male reproduction; HUMAN SEMINAL PLASMA; PROTECTS BULL SPERM; MALE-INFERTILITY; DNA-DAMAGE; CELL-DEATH; ANTIOXIDANT SUPPLEMENTATION; LIPID-PEROXIDATION; D-ASPARTATE; SPERMATOZOA; INHIBITION;
D O I
10.3390/antiox10071079
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Advanced paternal age is associated with increased sperm reactive oxygen species (ROS) and decreased fertilization and pregnancy rates. Sperm washing during infertility treatment provides an opportunity to reduce high sperm ROS concentrations associated with advanced paternal age through the addition of idebenone. Sperm from men aged >40 years and older CBAF1 mice (12-18 months), were treated with 5 mu M and 50 mu M of idebenone and intracellular and superoxide ROS concentrations assessed. Following in vitro fertilization (IVF), embryo development, blastocyst differentiation, DNA damage and cryosurvival, pregnancy and implantation rates and fetal and placental weights were assessed. Five mu M of idebenone given to aged human and mouse sperm reduced superoxide concentrations similar to 20% (p < 0.05), while both 5 and 50 mu M reduced sperm intracellular ROS concentrations in mice similar to 30% (p < 0.05). Following IVF, 5 mu M of idebenone to aged sperm increased fertilization rates (65% vs. 60%, p < 0.05), blastocyst total, trophectoderm and inner cell mass cell numbers (73 vs. 66, 53 vs. 47 and 27 vs. 24, respectively, p < 0.01). Treatment with idebenone also increased blastocyst cryosurvival rates (96% vs. 78%, p < 0.01) and implantation rates following embryo transfer (35% vs. 18%, p < 0.01). Placental weights were smaller (107 mg vs. 138 mg, p < 0.05), resulting in a larger fetal to placental weight ratio (8.3 vs. 6.3, p = 0.07) after sperm idebenone treatment. Increased sperm ROS concentrations associated with advanced paternal age are reduced with the addition of idebenone in vitro, and are associated with improved fertilization rates, embryo quality and implantation rates after IVF.
引用
收藏
页数:16
相关论文
共 26 条
  • [21] A minimally invasive clinical model to test sunscreen toxicity based on oxidative stress levels using microbiopsy and confocal microscopy - a proof of concept study
    Yamada, Miko
    Lin, Lynlee L.
    Hang, Lydia Y. T.
    Belt, Paul J.
    Soyer, H. Peter
    Raphael, Anthony P.
    Prow, Tarl W.
    INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 2020, 42 (05) : 462 - 470
  • [22] In Vitro Fertilization/Intracytoplasmic Sperm Injection with Autologous Oocytes in Healthy Women of Advanced Maternal Age: A Comparative Study Investigating Obstetric and Perinatal Outcomes Through Single Versus Double Embryo Transfer
    Reinolds, Ellen-Elena
    Tsiartas, Panagiotis
    Hadziosmanovic, Nermin
    Rodriguez-Wallberg, Kenny A.
    WOMENS HEALTH REPORTS, 2024, 5 (01): : 512 - 521
  • [23] Evaluation of Self-care Activities and Quality of Life in Patients With Type 2 Diabetes Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: the DePRO Proof-of-Concept Observational Study
    Mueller, Christian
    Schauerte, Isabel
    Martin, Stephan
    Irrgang, Valeska
    JMIR DIABETES, 2022, 7
  • [24] Evaluation of Self-Care Activities and Quality of Life in Patients With Type 2 Diabetes Mellitus Treated With Metformin Using the 2D Matrix Code of Outer Drug Packages as Patient Identifier: Protocol for the DePRO Proof-of-Concept Observational Study
    Mueller, Christian
    Schauerte, Isabel
    Martin, Stephan
    JMIR RESEARCH PROTOCOLS, 2021, 10 (01):
  • [25] A study to determine the efficacy of controlled ovarian hyperstimulation regimen using a gonadotropin releasing hormone agonist versus antagonist in women of advanced reproductive age with varying degrees of oocyte reserve on outcome following in vitro fertilization-embryo transfer
    Check, J. H.
    Choe, J. K.
    Cohen, R.
    Wilson, C.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2013, 40 (02): : 191 - 192
  • [26] Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium Phase I/II proof-of-concept study to explore the safety and efficacy of a tri-therapy approach using avelumab, palbociclib and axitinib in advanced/metastatic non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates
    Solomon, Benjamin
    Felip, Enriqueta
    Bar, Jair
    Berchem, Guy
    Bazhenova, Lyudmila
    Saintigny, Pierre
    Girard, Nicolas
    Sulaiman, Raed
    Bresson, Catherine
    Wunder, Fanny
    Lee, J. Jack
    Raynaud, Jacques
    Rubin, Eitan
    Young, Brandon
    Lazar, Vladimir
    Onn, Amir
    Jones, Brian Leyland
    Kurzrock, Razelle
    CANCER RESEARCH, 2019, 79 (13)